Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer (NPH)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00471029|
Recruitment Status : Unknown
Verified May 2007 by Pamela Youde Nethersole Eastern Hospital.
Recruitment status was: Recruiting
First Posted : May 9, 2007
Last Update Posted : May 9, 2007
|Condition or disease||Intervention/treatment||Phase|
|Peptic Ulcer||Drug: esomeprazole||Phase 4|
Peptic ulcer bleeding is a common medical emergency. Although primary hemostasis can be achieved by endoscopic hemostasis in more than 90% of cases, rebleeding during the first 72 hours is still common. The use of secretory inhibitors in ulcer bleeding had theoretical benefit in preventing rebleeding. In vitro, platelet aggregation and disaggregation, coagulation and fibrinolysis are strongly dependent on intra-gastric pH. When pH falls below 6.0, platelet disaggregation takes place and below 4.0, fibrin clots dissolved. Pharmacological studies have clearly shown that primed proton-pump inhibitor (PPI) infusion is superior to H2-receptor blocler (H2B) injection or infusion in maintaining high intra-gastric pH. Randomized trials had demonstrated the advantage of adjuvant use of intravenous or oral PPI in reducing rebleeding as compared to placebo. However, as Asian subjects generally have lower body weight and acid output than Caucasians, the dosage of PPI required for prevent rebleeding may be different. Lin et al had demonstrated that in an Asian population study, in order to show a significant clinical effect in prevent peptic ulcer rebleeding after endoscopic hemostasis, at least a 30% difference in duration in maintaining an intragastric pH >6 must be achieved. As there is substantial cost implication of routine use of high dose intravenous PPI infusion (80mg bolus + 8mg/hour for 72 hours, cost ~HKD$1100) against high dose oral esomeprazole (40mg BD for 3 days, cost ~HKD$60), the optimal doses and routes of administration of PPI in achieving effective acid suppression is needed to be clearly defined.
Patients presented with bleeding peptic ulcers (melena, hememtesis) will undergo endoscopy. If clean base peptic ulcer which dos not require endoscopic treatment is diagnosed, consented patients will randomly allocated into 2 groups using sealed envelopes containing a therapeutic option derived from a randomized table.
- Esomeprazole infusion (80mg bolus then 8mg/hour) (192mg/d)
- Esomeprazole Tablet oral 40mg 12 hourly (80mg/d)
A pH electrode with internal reference (Synetic) was inserted transnasally and positioned 10cm below the cardia. It was calibrated before and after the pH recording with standard buffer solutions of pH 7.00 and pH 1.00. The electrode was connected to a data logger (Mircodigitrapper, Synetic). At the end of 24hours recording, the data were transfer to a personal computer for analysis. Medication will be given after insertion of intra-gastric pH monitor probe.
Outcome measures Primary Outcome: total % Time pH > 6 & 4 Secondary outcome: Median intragastric pH & Time to reach pH 4 and 6
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Compare Gastric Acid Suppression of Esomeprazole by Oral or Intravenous Administration - A Randomized Trial|
|Study Start Date :||September 2005|
|Estimated Study Completion Date :||September 2007|
- percentage of time intragstric pH > 6 and > 4 [ Time Frame: 24hours after endoscopy ]
- Median intragastric pH [ Time Frame: 24hours after endoscopy ]
- time to attain intragastric pH 4 & 6 [ Time Frame: 24hours after endoscopy ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00471029
|Contact: Simon K.H. Wong, MBChB, FRCSEd, FHKAMfirstname.lastname@example.org|
|Pamela Youde Nethersole Eastern Hospital||Recruiting|
|Hong Kong, China|
|Contact: Simon KH Wong, MBChB email@example.com|
|Principal Investigator: Simon KH Wong, MBChB|
|Sub-Investigator: Michael KW Li, MD|
|Sub-Investigator: Geroge PC Yang, MBBS|
|Principal Investigator:||Simon K.H. Wong, MBChB, FRCSEd, FHKAM||Pamela Youde Nethersole Hospital - Surgery|
|Study Chair:||Michael K.W. Li, MD||PYNEH|